Anavex Life Sciences Corp (AVXL)

[sokol]

Boi:

Thank you for your post. I agree that not all sigma-1 agonists are the same. I add this in support:

Donepezil is a nonselective sigma-1 agonist as opposed to a sigma-1 receptor selective medication such as AVXL 2-73. Selective sigma-1 agonists show promise for treating dementia and other conditions.

"Although no sigma-1 receptor–selective medications are currently approved by the FDA, several currently marketed agents and other substances interact with sigma-1 receptors in a nonselective manner, such as fluvoxamine, donepezil, haloperidol, and pentazocine.".....

ANAVEX2-73: The leading sigma-1 agonist under development is ANAVEX2-73, an amino-tetrahydrofuran derivative and mixed muscarinic/sigma-1 receptor agonist.16 At present, 3 active clinical trials involve ANAVEX2-73: one for Parkinson disease with dementia and 2 for Alzheimer disease.17 Another clinical trial for Rett syndrome is planned, announced in October 2018 by manufacturer Anavex Life Sciences."...

https://www.neurologylive.com/journals/neurologylive/2019/april-2019/sigma1-agonists-offer-combination-approach-to-dementia-symptoms

"ANAVEX 2-73 (AV2-73) is a novel cholinergic and selective sigma-1 receptor agonist under development as potential agent for Alzheimer’s disease or dementia with neuroprotective properties. "

https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2321147

It seems to me, very much a non-expert, that comparing selective sigma-1 agonists with non-selective sigma-1 agonists is an apples/oranges comparison.

Furthermore, AVXL 2-73 “... it is a mixed ligand for sigma1/muscarinic receptors...”, and that needs to be kept in mind in making comparisons.